聚乙二醇干扰素 alfa-2b 治疗慢性乙型肝炎患者的血清蛋白。

Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b.

机构信息

Medical Microbiology, Interdisciplinary Program, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.

出版信息

World J Gastroenterol. 2013 Aug 21;19(31):5067-75. doi: 10.3748/wjg.v19.i31.5067.

DOI:10.3748/wjg.v19.i31.5067

PMID:23964140

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3746378/

Abstract

AIM

To study the differential protein profile in serum of hepatitis B patients.

METHODS

Serum samples were obtained from patients with chronic hepatitis B who were receiving peginterferon alfa-2b. The serum samples were subjected to albumin depletion and analyzed by two-dimensional gel electrophoresis (2-DE). Differentially expressed protein spots were identified by electrospray ionization-quadrupole time-of-flight mass spectrometry. Alpha-2-HS-glycoprotein, complement component C3c and CD5 antigen were further analyzed by an enzyme-linked immunosorbent assay and immunonephelometry.

RESULTS

Nineteen patients with HBeAg-positive chronic hepatitis B (CHB) were studied. These patients were followed for at least 1 year after treatment and were classified according to their treatment response: responders (n = 9) and non-responders (n = 10). 2-DE and MS/MS analysis were performed to compare the serum proteins before initiating peginterferon alfa-2b. From the quantitative analysis of the 2-D gel, 7 proteins were detected between the two groups at different levels before treatment. Among these potential candidates, serum levels of alpha-2-HS-glycoprotein, complement component C3c and CD5 antigen-like precursor were further analyzed. In the validation phase, 23 subjects, 9 sustained responders and 14 non-responders, were recruited. Interestingly, the levels of alpha-2-HS-glycoprotein and complement component C3c were elevated in the serum of the non-responders compared to the responders.

CONCLUSION

Serum alpha-2-HS-glycoprotein and complement component C3c may be potential serum biomarkers in predicting the treatment response of peginterferon alfa-2b in patients with CHB prior to treatment.

摘要

目的

研究乙型肝炎患者血清中的差异蛋白质谱。

方法

从接受聚乙二醇干扰素 alfa-2b 治疗的慢性乙型肝炎患者中获得血清样本。将血清样本进行白蛋白耗尽处理，并通过二维凝胶电泳（2-DE）进行分析。通过电喷雾电离-四极杆飞行时间质谱鉴定差异表达的蛋白质斑点。进一步通过酶联免疫吸附试验和免疫比浊法分析α-2-HS-糖蛋白、补体成分 C3c 和 CD5 抗原。

结果

研究了 19 例 HBeAg 阳性慢性乙型肝炎（CHB）患者。这些患者在治疗后至少随访 1 年，并根据治疗反应进行分类：应答者（n=9）和无应答者（n=10）。在开始聚乙二醇干扰素 alfa-2b 治疗前，进行 2-DE 和 MS/MS 分析以比较血清蛋白。通过定量分析 2-DE 凝胶，在治疗前两组之间检测到 7 种不同水平的蛋白质。在这些潜在候选物中，进一步分析了血清α-2-HS-糖蛋白、补体成分 C3c 和 CD5 抗原样前体的水平。在验证阶段，招募了 23 名受试者，9 名持续应答者和 14 名无应答者。有趣的是，无应答者血清中的α-2-HS-糖蛋白和补体成分 C3c 水平高于应答者。